Table 2.
Oral contraceptive pill (OCP) types and menstrual status descriptions from included studies comparing OCP users and non-users following matched resistance exercise training interventions
| Study | Duration of OCP use mean ± SD |
OCP type | OCP brand name | OCP dosage | Non-user criteria |
|---|---|---|---|---|---|
| Dalgaard et al., 2019 | 6.1 ± 5.0 years |
Third-generation combined monophasic (n = 7) |
Lindynette | 75 μg gestodene and 30 μg ethinyl oestradiol | n = 14; had regular menstrual cycles (self-report) for at least 1 year (within the range of 24–35 days) |
|
Third-generation combined monophasic (n = 5) |
Gestonette | 75 μg gestodene and 20 μg ethinyl oestradiol | |||
|
Third-generation combined monophasic (n = 2) |
Novynette | 150 μg desogestrel and 20 μg ethinyl oestradiol | |||
| Dalgaard et al., 2022* | 6.5 ± 2.5 years |
Second-generation combined monophasic (n = 17) |
Femicept | 150 μg levonorgestrel and 30 μg ethinyl oestradiol | n = 18; had not been using any form of hormonal contraceptive for the past 3 months and reported that they had experienced a regular menstrual cycle (menses every 24–35 days) at last 3 months or more before the intervention |
|
Second-generation combined monophasic (n = 3) |
Cilest | 250 μg norgestimate and 35 μg ethinyl oestradiol | |||
| Nichols et al., 2008 | NR |
Second-generation combined (n = 13) |
NR | NR | n = 18; had regular menstrual cycles (menses every 25–35 days) |
| Oxfeldt et al., 2020* | 6.5 ± 2.5 years |
Second-generation combined monophasic (n = 17) |
Femicept | 150 μg levonorgestrel and 30 μg ethinyl oestradiol | n = 18; had not been using any form of hormonal contraceptive for the past 3 months and reported that they had experienced a regular menstrual cycle (menses every 24–35 days) at last 3 months or more before the intervention |
|
Second-generation combined monophasic (n = 3) |
Cilest | 250 μg norgestimate and 35 μg ethinyl oestradiol | |||
| Reichman and Lee, 2021 | NR | Oral contraceptives (n = 34) |
Orthotricycle, Orthonovum, Orthocept, Desogen, Nordette, Alesse, Tivora, Estrostep, Loestrin |
NR | n = 38; no information was available on the menstrual status of OCP non-users |
| Romance et al., 2019 | NR |
Second-generation (n = 4) |
NR | 150 μg levonorgestrel and 30 μg ethinyl oestradiol | n = 11; had reported to have regular menstrual cycles (i.e. occurring on a 28- to 30-day cycle) and had not taken any form of synthetic oestrogen or progesterone for at least 6 months prior to the study |
|
Third-generation (n = 8) |
NR | 50 μg gestodene and 30 μg ethinyl oestradiol | |||
| Sung et al., 2022 | ≥ 1 year prior to study |
Second-generation combined monophasic (n = 3) |
Anastrella 28 | 150 μg levonorgestrel and 30 μg ethinyl oestradiol | n = 40; had no OCP use or hormonal treatment in the past year; 2 months of monitoring daily body temperature were performed to establish regularity of menstrual cycle prior to beginning intervention. Average menstrual cycle duration throughout intervention was 28.2 ± 1.2 days |
|
Second-generation combined monophasic (n = 10) |
Cilest | 250 μg norgestimate and 35 μg ethinyl oestradiol | |||
|
Second-generation combined monophasic (n = 8) |
Femicept | 150 μg levonorgestrel and 30 μg ethinyl oestradiol | |||
|
Second-generation combined monophasic (n = 9) |
Loette | 100 μg levonorgestrel and 20 μg ethinyl oestradiol | |||
|
Second-generation combined monophasic (n = 4) |
Microstad | 150 μg levonorgestrel and 30 μg ethinyl oestradiol | |||
| Wikstrom-Frisen et al., 2017 | NR |
Combined monophasic (n = 11) |
NR | NR | n = 44; had a regular menstrual cycle of 28 days (acceptable 21–35 days) |
| Combined triphasic (n = 20) | NR | NR |
NR not reported
*Shared participants